Is watch and wait still acceptable for patients with low-grade follicular lymphoma?

James O. Armitage, Dan L. Longo

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Follicular lymphoma (FL) represents more than 20% of all non-Hodgkin lymphomas worldwide and approximately 30% of the non-Hodgkin lymphomas diagnosed in the United States. Although occasionally localized at the time of diagnosis, most patients have disseminated disease. However, patients are frequently asymptomatic, and this, in combination with a long median survival, led to the initial studies of observing asymptomatic patients without initial therapy, ie, "watch and wait." Since the initial report of watch and wait as a treatment strategy for patients with low-grade FL, our understanding of the biology of the disease has advanced; multiple active new agents have been introduced into practice, and the survival of patients with low-grade FL has improved. Given these changes, is watch and wait still an acceptable treatment recommendation for a newly diagnosed patient with low-grade FL? (Blood. 2016;127(23):2804-2808).

Original languageEnglish (US)
Pages (from-to)2804-2808
Number of pages5
Issue number23
StatePublished - Jun 9 2016

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Is watch and wait still acceptable for patients with low-grade follicular lymphoma?'. Together they form a unique fingerprint.

Cite this